Quick Answer
Artiva Biotherapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $26.70 million for the year ending 2025.
- Artiva Biotherapeutics, Inc. showed a decrease of -33.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Artiva Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $53.70 million | Q3 2023: $65.89 million | Q1 2024: $48.20 million | Q2 2024: $34.25 million | Q3 2024: $55.88 million | Q1 2025: $30.40 million | Q2 2025: $28.47 million | Q3 2025: $25.51 million.
- Over the full 3 years of available data (2023 to 2025), Artiva Biotherapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 50.1%.
- Historical annual values: Fiscal year 2025: $26.70 million | Fiscal year 2024: $40.24 million | Fiscal year 2023: $53.50 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: